Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained a drug registration certificate from the Chinese drug administration for Pentazocine injection, according to a Hong Kong Stock Exchange filing on Wednesday.
The certificate shows that the drug, which is suitable for the treatment of various types of severe chronic pain, passed the regulator's quality standards for its production and sales, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.